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WE PRESENT A simple risk prediction formula for arteriovenous malformation hemorrhage. Natural history studies 
have shown an annual risk of hemorrhage of 2 to 4% for patients with brain arteriovenous malformations. Although 
decision analysis programs and biostatistical models are available to predict long-term risks of hemorrhage, we 
hypothesized that there was varying knowledge regarding the use of such programs within the general neurosurgical 
community. To obtain information on the current use of risk data, we performed a survey of neurosurgeons at 
national meetings in 1988 and 1994. Neurosurgeons were asked to define the risk for arteriovenous malformation 
hemorrhage in the young adult patient over a 20- to 30-year period, given a 3 or 4% annual risk of hemorrhage. A 
wide range of answers was obtained (1-100% risk), and many different methods of calculation were used. The use 
of the multiplicative law of probability formula requires only knowledge of patient age and annual hemorrhage risk. 
Risk of hemorrhage =  1 -  (risk of no hemorrhage)expected years of remaining lifc. The assumptions pertaining to this 
multiplicative formula include a constant yearly risk of hemorrhage and the independent behavior of all years of 
observation. We calculated the predictions of risk of hemorrhage across all age groups, as modified by published 
survival data. We think the use of this formula is justified by published natural history data across different ages and 
populations and that it is a simple and reasonable alternative to other methods of calculation. (Neurosurgery 
37:851-855, 1995)
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the ways in which they use published natural history data 
(usually stated as an annual risk of bleeding) to advise pa­
tients about their long-term (lifetime) prognosis; and 2) to 
propose a simple formula for calculating the risk of subse­
quent bleeding over a prolonged period of time, based on the 
multiplicative law of probability (5). This formula requires a 
number of assumptions and, as proposed, does not take into 
account some of the published risk factors for subsequent 
bleeding, but it is simple to use and may be a reasonable 
alternative for clinical use. ,
The problems with such an approach to risk estimation 
include population heterogeneity, a variable natural history, 
and the existence of patient sub-groups with different risks for 
initial and subsequent hemorrhage (e.g., pregnant women, 
patients with AVMs and aneurysms, patients with AVMs 
with venous outflow restriction) (3, 13, 19, 23, 26, 31, 33, 34). 
Although the estimated 2 to 4% yearly risk of hemorrhage has 
been substantiated in different countries and appears not to 
vary significantly through the course of follow-up, indicating
Recent studies have agreed that the annual risk for hem­orrhage from a brain arteriovenous malformation (AVM) is ~2 to 4% (4, 6, 11, 12, 16, 17, 24, 25). This is useful information, but it needs to be used by surgeons t  
advise patients about the risk of bleeding over a number of 
years or over the remainder of their lives. One alternative is 
for the surgeon to inform the patient of a 2 to 4% risk per year. 
The interpretation of that figure is then left up to the patient. 
Most surgeons are asked for or think that they should provide 
the patient with a summary of the risk over a longer time 
period to give them a more representative idea of the natural 
history. Such information is often used as the basis for a 
decision to treat an AVM, along with expected treatment risks 
(29, 30). A decision analysis model has been published; it 
takes into account a number of risk factors and the patients' 
perception of the possible outcomes (9). This appears to be a 
good model, but it may be difficult to apply in day-to-day 
clinical situations. The two purposes of our study were as 
follows: 1) to survey practicing neurosurgeons and examine
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some degree of population homogeneity and predictable nat­
ural history, the interpretation of population data to specific 
patients must be approached with caution. It is not our pur­
pose to use this formula and its assumptions to derive hem­
orrhage rates that represent mathematical fact but rather to 
derive rates that are reasonable, easy to use, and make sense 
with previously published clinical studies.
METHODS 
The proposed method of calculation
If we assume that the annual risk of bleeding is 3% (0.03), 
then the chance of remaining free of hemorrhage for 1 year is
1 — 0.03 = 0.97. The chance of remaining hemorrhage-free for
2 years is calculated by applying the multiplicative law of 
probability (5) as follows: 0.97 X 0.97 = 0.94. The chance of 
having no bleeds for y years = 0.97y.
Patients will be at risk of subsequent bleeding for the rest 
of their lives. Based on the age of presentation, a patient's 
"expected years of remaining life" can be determined from 
life tables (1). Thus, the patients' cumulative chance of 
staying hemorrhage-free for life is equal to the following:
0.97e*pected y8ars of ufe or the risk of bleeding (at least
OnCG) = 1_0 9 7 e x P e c te d  years r e m a in in g  l ife
; Consider this example. A 25-year-old man presents with a 
seizure and is found to have a small frontal AVM. His life 
Expectancy is 77 years; he has 52 expected years of life re­
maining (1). Assuming a risk of hemorrhage of 3% per year, 
the risk is calculated as follows: risk = 1 -  0.9752 = 0.80 or 
80%. This calculation makes a number of assumptions as 
follows: 1) that the yearly risk of hemorrhage is constant (in an 
individual and a population); and 2) that the risk of hemor­
rhage in arty given year is not influenced by (i.e., is indepen­
dent of) events in other years.
Mortality from bleeding does not affect this calculation. We 
are calculating the probability of remaining free of bleeds over 
a period of time, and we are assuming that each year the 
probability of not bleeding is 0.97. Among the 0.03 patients 
who have: bled, some (~5-20%) will die but this will not affect 
the proportion who are alive and hemorrhage-free at the end 
of the 1st year and remain at risk. The probability of living
and not bleeding over x years then is 0.97* and the probability 
of bleeding (whether or not death occurs from the bleed) = 
1 -  0.97*.
A survey of neurosurgeons
We performed a survey of a convenience sample of neuro­
surgeons in 1988 at the meeting of the American Association 
of Neurological Surgeons in Toronto, Ontario, Canada. Each 
surgeon was stratified according to resident or attending sta­
tus. Each individual was given an unlimited time period to 
answer one question. The following question was posed: "A 
neurologically intact 42-year-old woman presents with an 
arteriovenous malformation. She wishes to know what is the 
chance of having a hemorrhage in her lifetime, assuming a life 
expectancy of 30 more years and a 3% yearly risk of hemor­
rhage. Provide your answer and method of calculation."
In 1994, we administered a second random survey at the 
meeting of the American Association of Neurological Sur­
geons in San Diego, CA. The following question was posed: 
"A 25-year-old male presents with headache and is found to 
have a 2-cm arteriovenous malformation in the left frontal 
lobe. What is his risk for sustaining a hemorrhage over the 
next 20 years, assuming a 4% yearly risk for hemorrhage?" 
Again, information on resident or attending neurosurgeon 
status was requested.
RESULTS 
The application of the formula
Risk estimates for patients from birth to age 85 years are 
calculated (assuming an annual risk of 3 or 4%) and presented 
in Table 1.
The surveys
In 1988, 16 individuals were surveyed. Eight were resi­
dents, and eight were attending neurosurgeons. One surgeon 
(6%) estimated the risk to be 60%. Three "guessed" at the risk 
and gave answers from 50 to 80%. Six respondents gave very 
high risks of 90 to 100%, and two answered 30%. Four gave no
TABLE 1. Lifetime Risk for Arteriovenous Malformation Hemorrhage













0 76 79 90 96
15 62 71 85 92
25 ■Vi.:''. . . 5 2 ' 65 80 88
35 43 58 73 83
45 34 50 65 75
55 25 40 53 64
65 18 31 42 52
75 11 20 29 36
85 . 6 ■. 11 17 22
1 Estim ate to 1992 Preliminary Life Tables prepared by Metropolitan Life Insurance Company (1)
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response. Using the multiplicative law of probability, the risk 
of hemorrhage is calculated to be 60%.
In the 1994 survey, 103 neurosurgeons were sampled. 
Twenty-eight of the total respondents were resident neuro­
surgeons, 72 were attending neurosurgeons, and 3 did not 
provide their level of training status. Eight individuals (8%) 
said they would use the multiplicative law of probability or 
gave a risk of 56%. They were equally distributed between 
residents and attending neurosurgeons. Twenty-four sur­
geons (23%) provided a "guess" between 50 and 79%. Fifty 
surgeons (49%) calculated an 80% total risk by multiplying a 
4% per year risk by 20 years. Five surgeons (5%) calculated 4% 
as the total risk for hemorrhage. Fifteen (15%) surgeons pro­
vided a range of answers between 1 and 49% risk or greater 
than 80% risk, and one surgeon provided no answer. Using 
the multiplicative law of probability, the risk in this survey is 
calculated to be 56%. We considered a close answer to be 
within 25% of that calculated; this was provided by 18% of the 
surgeons.
DISCUSSIO N
The effort put forth by numerous institutions to understand 
the natural history of untreated AVMs has provided consis­
tent information. The annual risk of hemorrhage from an 
untreated or incompletely obliterated AVM was found to be 
between 2 and 4% per year (4, 24). These natural history rates 
of subsequent bleeds are the basis for making management 
decisions. We were interested in the way surgeons used this 
information when talking to a hypothetical patient. In both 
surveys, we found that surgeons provided a wide range of 
responses and used a number of different methods to arrive at 
their response. Several authors have proposed detailed tech­
niques for decision making based on published rates of AVM 
subsequent bleeds. Fisher (9) used Markov analysis to com­
pare surgical and conservative options for a hypothetical pa­
tient weighing the factors of age, morbidity and mortality 
rates, risks of subsequent bleeds, and patient desires. Al­
though such techniques may be valid, they are complex and 
may be difficult to use in the clinical setting. Iansek et al. (15) 
used an annual AVM hemorrhage risk of 1% and a surgical 
mortality risk of 8 to 10%/ in addition to other predictors, to 
conclude that conservative management offered less atten­
dant risk than surgical resection of AVMs, even over the long 
term. In that report, the authors used a hemorrhage rate lower 
than that reported in most studies and a surgical mortality 
rate higher than what could be achieved at most centers 
during the 1980s. Decision analysis techniques have also been 
applied to aneurysm data (8, 32).
Risk estimates for AVM hemorrhage are important because 
of the crucial role they play in guiding treatment. Successful 
complete microsurgical resection immediately eliminates the 
long-term risk of hemorrhage (2, 13, 14). For management 
options, such as stereotactic radiosurgery (21), endovascular 
embolization, or staged procedures, a latency interval before 
obliteration renders mandatory some consideration of the 
hemorrhage risk. If no treatment (conservative observation) is 
pursued, then the lifetime risks for AVM hemorrhage and
potential mortality must be accepted and understood. We 
selected a 3% annual risk for Table 1 as a conservative estimate 
between published data of 2 and 4%.
Because this formula demands that all predicted years act 
independently (a uniform natural history), the annual hem­
orrhage risk must be properly interpreted. For discussion, we 
will assume an annual risk of 3%. A common error is to 
multiply the 3% risk by the number of years of interest (the 
method used by many of the neurosurgeons in our survey). 
For example, a 10-year-old with 70 years of estimated life 
remaining does not have a 210% chance of lifetime hemor­
rhage. Luessenhop and Rosa (20) plotted patient age versus 
percentage probability of bleeding. Although their graph 
showed a 100% lifetime hemorrhage risk for patients younger 
than 40 years (which they admitted was incorrect), they plot­
ted the risk for patients older than 40 years by directly mul­
tiplying 3% by the number of years remaining (i.e., a 50-year- 
old living to age 75 has a 75% chance of bleeding). The actual 
risk calculated by the multiplicative law of probability is 53% 
(1 — 0.9725). This graph was later cited and reprinted in the 
natural history of AVMs review provided by Wilkins (36).
The application of the multiplicative law of probability is 
proposed as a simple and reasonable alternative method for 
AVM hemorrhage risk calculation. A number of assumptions 
are required in the application of this law and are discussed 
below.
Assumption 1: population homogeneity
Some degree of population homogeneity has been demon­
strated by the results of studies performed in different na­
tions. American (4,11,12), Japanese (16), Swedish (10), French 
(17), British (6), and Finnish (24) groups provided consistent 
data on the long-term risk of hemorrhage in untreated pa­
tients. Although individual patients within a population vary 
considerably in regard to age, AVM location, size, and hemo­
dynamic pattern, the presence of associated aneurysms, and 
systemic physiological states (e.g., pregnancy, coagulopathy), 
the populations, as a whole, seem to be remarkably uniform. 
The assumption of overall population homogeneity seems 
reasonable.
Assumption 2: uniform natural history
To predict hemorrhage risk over the course of a lifetime, 
this formula assumes that each year of prediction is indepen­
dent. For this to be true, the annual 3% hemorrhage risk must 
be applicable to young, middle-aged, and elderly patients; 
The traditionally held concept that the risk of an AVM hem­
orrhage is significantly lower in the elderly, does not hold up 
in reported studies. Although most series indicate a higher 
rate of clinical presentation at the 20- to 40-year age interval
(27), the actual proportion of hemorrhagic to nonhemorrhagic 
AVM presentations remains fairly constant through the adult 
years. Parkinson and Bachers (25) studied 100 consecutive 
patients with brain AVMs and stratified the percentage of 
hemorrhagic presentations by decade; no significant differ­
ences were seen. In the study by Ondra et al. (24), with a mean 
follow-up of 24 years, the hemorrhage rates remained con­
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stant through 5-year stratifications of the first 20 years of the 
study period (with some decline thereafter), regardless of 
patient age upon entrance into the study. Pregnancy (7) or 
hypertension might predispose patients to hemorrhage, but 
their significance in population risks is low. Robinson et al.
(28) found no increase in risk of hemorrhage with increasing 
gestational age. As noted above, the hemodynamic factor of 
venous outflow restriction or the presence of proximal or 
intranidal aneurysms also might increase the risk for hemor­
rhage and must be identified and considered in individual 
patients. Although some reports note the occurrence of the 
spontaneous enlargement or regression of AVMs, this phe­
nomenon appears to be infrequent enough as to not signifi­
cantly contribute to a changing natural history (22, 35).
The risk of hemorrhage in the initial posthemorrhage year 
was reported by Graf et al. (12) to be 6%. Fults and Kelly (11) 
reported a lst-year subsequent bleeding rate of 17.9% in their 
study, which declined to 2% per year after 10 years. However, 
in the largest study reported by Ondra et al. (24), the authors 
found that the 4% annual hemorrhage rate was constant over 
the 20-year follow-up interval and did not vary regardless of 
the manner of presentation (24). Thus, we found it reasonable 
not to include for the lifetime calculation risk a potentially 
short-term increased rate after a first bleed.
Few studies have addressed the hemorrhage risk of 
AVMs in children (age, <18 yr), which may be higher than 
in adults. Kondziolka et al. (18) reported 132 children with 
AVMs accrued over a 40-year period, with hemorrhage 
being responsible for 79% of clinical presentations. The 
higher proportion of patients with posterior fossa AVMs 
that present earlier in life with hemorrhage (these do not 
present with seizures) and potentially larger number of 
smaller lesions may explain this higher bleeding tendency. 
These reported observations do not mean, however, that 
AVMs in children will present with hemorrhage at a higher 
rate (e.g., >2-4%/yr) but that those that do, do so with 
hemorrhage. Because there is evidence that suggests some 
degree of natural history uniformity across different age 
groups, we thought this assumption was valid.
For AVMs, all current treatment alternatives mandate an 
understanding of the natural history of the risk of hemor­
rhage. Such an understanding is not only important for pa­
tient education and for comparison to our surgical results but 
also for the justification of the selection of a specific manage­
ment strategy. The simplicity of this formula and its appro­
priateness for most patients with AVMs within the frame­
work of addressed assumptions makes it a reasonable 
alternative for physicians who are managing these difficult 
problems.
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COMMENTS
T h is succinct article describes a practical and sound method 
o f  estimating the life-long risk of hemorrhage from an arte­
r ioven ou s malformation (AVM) for a particular patient. It also 
a llo w s  the surgeon to make an estimate of the risk for a 
d e fin e d  period of time. I think the patients generally have as 
m u c h  trouble as I have understanding the meaning of a "3 to
4% risk of hemorrhage every year." The frequent follow-up 
question from the patients is, "Does that mean that I will 
surely die from this AVM if I live for x number of years-an 
inevitable conclusion if the patient is 20 years old and the 
annual risk of hemorrhage is multiplied by the actuarially 
expected 50 or 55 years of survival. The authors have pro­
vided an intelligent answer to this question.
Roberto C. Heros
Miami, Florida
The authors provide us with an appropriate and useful 
analysis for predicting the risks of hemorrhage secondary to 
cerebral AVM. The statistical methods are sound and will 





Neurosurgeons who deal with patients who have survived 
the rupture of an AVM are almost always asked to prognos­
ticate with respect to future risk, because this is clearly a 
determining factor for a patient in accepting surgical excision 
or some other form of therapy that is not entirely risk-free. 
This approach (the use of the multiplicative law of probability 
formula requiring only patient age and annual hemorrhage 
risk) seems to be reasonable.
The authors recognize the inherent limitations of this 
method, which include but are not restricted to the following: 
1) some patients are going to die from their recurrent hemor­
rhages; 2) pregnancy may predispose a patient to an increased 
risk of hemorrhage; 3) the risk of hemorrhage may be greater 
in the months immediately after the rupture of an AVM; 4) 
hemorrhage in pediatric patients may be associated with a 
higher rate of subsequent hemorrhage than in older patients; 
5) patients with certain AVMs, such as those in the posterior 
fossa, have a higher mortality rate, and patients with certain 
AVMs, such as those with venous constriction or associated 
aneurysms, may be at higher risk of hemorrhage and death. 
All these limitations aside, it is still desirable to be able to 
show the patients this projection as an addition to the mere 
statement that their risk of hemorrhage is "2 to 4% per year."
I intend to have a copy of the table by Kondziolka et al. in 
my desk drawer, and I will use it not only in advising patients 
who have had AVM hemorrhage but also patients with mul­
tiple aneurysms who have had an aneurysmal rupture, be­
cause the bleeding rates are about the same. Are the differ­
ences in life expectancy between men and women not 
sufficiently great? Would it not have been scientifically useful 
to prepare separate lifetime risk tables for men and women?
Bryce K.A. Weir
Chicago, Illinois
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